Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Vascular Sales Remain Steady Despite Cypher Competition

This article was originally published in The Gray Sheet

Executive Summary

Myocardial cell replacement is among therapies Medtronic's vascular unit is striving to develop to curb reliance on coronary stent sales
Advertisement

Related Content

Medtronic Gets To Heart Of Cell Therapy Through Genzyme Collaboration
Medtronic Biotech Presence: “Pawn Or Rook?” Is VP Oesterle’s Challenge
Wireless CareLink, “Virtual” Cath Labs Bring IT Emphasis To Medtronic CRT
Ethics Code Adopted By Industry; DoJ Launches Medtronic Kickback Probe
DES Utilization Guidelines Give Guidant Comfort; J&J Revisits Cypher Pricing
Guidant Revenue Advances 20% In Q2 Despite Struggles In U.S. Stent Market
Medtronic Micro-Driver
Guidant/DoJ Probe Details Postmarket Reporting Meltdown With AAA Device
Medtronic Broadens Drug Delivery Options With EndoBionics Purchase
Bioheart Pursues OrCel Cardiac Regeneration; Ortec Chases Ulcer Claims
Advertisement
UsernamePublicRestriction

Register

MT018873

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel